Skip to main content
ELUT
NASDAQ Life Sciences

Elutia Posts $1.1M Q3 Sales, Confirms NXT-41x FDA Filing This Quarter With $29.1M Cash

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$0.751
Mkt Cap
$33.257M
52W Low
$0.5
52W High
$1.385
52W Position info
50% above low
Off High info
46% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

ELUT sits 50% above its 52-week low of $0.5.

Summary

Elutia reported third-quarter net sales of $1.1 million, up 20.4% from $0.9 million a year earlier, with adjusted gross margin of 85.5%. Net loss narrowed to $1.3 million from $3.9 million, helped by $5.2 million of income from discontinued operations, while the continuing-operation loss widened to $6.5 million as R&D spending rose $1.9 million on the NXT-41 and NXT-41x programs. Cash stood at $29.1 million at September 30, before the $8 million Boston Scientific holdback received October 1. Management says the three August funding moves — the Avenue Capital loan, the SimpliDerm sale and the escrow release — added $26 million in 51 days without an equity offering, enough to fund operations through NXT-41x clearance and its first full launch year. The near-term driver is regulatory: NXT-41 clearance is expected this quarter and the NXT-41x submission is planned for Q4 2026, with a clearance decision anticipated in the first half of 2027. The company still faces a Nasdaq minimum-bid issue with the stock at $0.75, and a Cardiovascular sale process is targeted for 2026 but is not needed for the stated runway.

At the time of this announcement, ELUT was trading at $0.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $33.3M. The 52-week trading range was $0.50 to $1.39. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

ELUT - Latest Insights

ELUT
Nov 05, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.7509
Real-time Price: $0.7855 info
Change: +$0.0346 (+5%) info
Market Cap: $33.257M info
ELUT
Aug 21, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.9509
Real-time Price: $0.7855 info
Change: -$0.1654 (-17%) info
Market Cap: $33.257M info
ELUT
Aug 14, 2026, 4:45 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.941
Real-time Price: $0.7855 info
Change: -$0.1555 (-17%) info
Market Cap: $33.257M info
ELUT
Aug 13, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.871701
Real-time Price: $0.7855 info
Change: -$0.086201 (-10%) info
Market Cap: $33.257M info
ELUT
Aug 13, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.7914
Real-time Price: $0.7855 info
Change: -$0.0059 (-0.75%) info
Market Cap: $33.257M info